XML 66 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and Other Intangibles (Tables)
3 Months Ended
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the three months ended March 31, 2020 were as follows (in thousands):
 
Branded Pharmaceuticals
 
Sterile Injectables
 
Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Goodwill as of December 31, 2019
$
828,818

 
$
2,731,193

 
$

 
$
35,173

 
$
3,595,184

Effect of currency translation

 

 

 
(2,387
)
 
(2,387
)
Goodwill impairment charges

 

 

 
(32,786
)
 
(32,786
)
Goodwill as of March 31, 2020
$
828,818

 
$
2,731,193

 
$

 
$

 
$
3,560,011


The carrying amounts of goodwill at March 31, 2020 and December 31, 2019 are net of the following accumulated impairments (in thousands):
 
Branded Pharmaceuticals
 
Sterile Injectables
 
Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Accumulated impairment losses as of December 31, 2019
$
855,810

 
$

 
$
3,142,657

 
$
500,417

 
$
4,498,884

Accumulated impairment losses as of March 31, 2020
$
855,810

 
$

 
$
3,142,657

 
$
494,499

 
$
4,492,966


Schedule of other intangible assets
Changes in the amount of other intangible assets for the three months ended March 31, 2020 were as follows (in thousands):
Cost basis:
Balance as of December 31, 2019
 
Acquisitions
 
Impairments
 
Effect of Currency Translation
 
Balance as of March 31, 2020
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
In-process research and development
$
93,900

 
$

 
$

 
$

 
$
93,900

Total indefinite-lived intangibles
$
93,900

 
$

 
$

 
$

 
$
93,900

Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 14 years)
$
457,402

 
$

 
$
(8,700
)
 
$

 
$
448,702

Tradenames
6,409

 

 

 

 
6,409

Developed technology (weighted average life of 11 years)
5,844,439

 

 
(55,051
)
 
(19,839
)
 
5,769,549

Total finite-lived intangibles (weighted average life of 11 years)
$
6,308,250

 
$

 
$
(63,751
)
 
$
(19,839
)
 
$
6,224,660

Total other intangibles
$
6,402,150

 
$

 
$
(63,751
)
 
$
(19,839
)
 
$
6,318,560

 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2019
 
Amortization
 
Impairments
 
Effect of Currency Translation
 
Balance as of March 31, 2020
Finite-lived intangibles:
 
 
 
 
 
 
 
 
 
Licenses
$
(410,336
)
 
$
(2,429
)
 
$

 
$

 
$
(412,765
)
Tradenames
(6,409
)
 

 

 

 
(6,409
)
Developed technology
(3,414,138
)
 
(114,808
)
 

 
11,934

 
(3,517,012
)
Total other intangibles
$
(3,830,883
)
 
$
(117,237
)
 
$

 
$
11,934

 
$
(3,936,186
)
Net other intangibles
$
2,571,267

 
 
 
 
 
 
 
$
2,382,374


Schedule of future amortization expense Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2019 is as follows (in thousands):
2020
$
427,824

2021
$
389,418

2022
$
373,293

2023
$
331,379

2024
$
292,903


Schedule of intangible asset impairment charges including goodwill
During the three months ended March 31, 2020 and 2019, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):
 
Three Months Ended March 31,
 
2020
 
2019
Goodwill impairment charges
$
32,786

 
$
86,000

Other intangible asset impairment charges
$
63,751

 
$
78,700